RT Journal Article
SR Electronic
T1 Impulsivity Facets and Substance Use Involvement: Insights from Genomic Structural Equation Modeling
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.24.24315331
DO 10.1101/2024.10.24.24315331
A1 Vilar-Ribó, Laura
A1 Hatoum, Alexander S
A1 Grotzinger, Andrew D
A1 Mallard, Travis T
A1 23andMe Research Team
A1 Elson, Sarah
A1 Fontanillas, Pierre
A1 Palmer, Abraham A
A1 Gustavson, Daniel E
A1 Sanchez-Roige, Sandra
YR 2024
UL http://medrxiv.org/content/early/2024/10/25/2024.10.24.24315331.abstract
AB Background Impulsivity is a multidimensional trait associated with substance use disorders (SUDs), but the relationship between distinct impulsivity facets and stages of substance use involvement remains unclear.Methods We used genomic structural equation modeling and genome-wide association studies (N=79,729-903,147) based on individuals of European ancestry to examine the latent genetic architecture of impulsivity and substance use behaviors. We included GWAS data from nine impulsivity traits and seven substance use (SU) and SUD traits.Results We found that the SU and SUD factors were strongly genetically inter-correlated (rG=0.77) but their associations with impulsivity factors differed. Lack of premeditation, negative and positive urgency were equally positively genetically correlated with both the SU (rG=.0.30-0.50) and SUD (rG=0.37-0.47) factors; sensation seeking was more strongly genetically correlated with the SU factor (rG=0.27 vs. rG=0.10); delay discounting was more strongly genetically correlated with the SUD factor (rG=0.32 vs. rG=0.21); and lack of perseverance was only weakly genetically correlated with the SU factor (rG=0.09). After controlling for the genetic correlation between SU/SUD, we found that lack of premeditation and positive urgency were independently genetically associated with both the SU (β=0.39, β=0.28, respectively) and SUD factors (β=0.28, β=0.19, respectively); sensation seeking and lack of perseverance were independently genetically associated with the SU factor (β=0.46, β=0.19, respectively); and negative urgency and delay discounting were independently genetically associated with the SUD factor (β=0.34, β=0.39, respectively).Conclusions Our findings show that specific impulsivity facets confer risk for distinct stages of substance use involvement, with potential implications for SUDs prevention and treatment.Competing Interest StatementS.E., P.F., and 23andMe Research Team are employed by and hold stock or stock options in 23andMe, Inc. All other authors report no conflicts of interest.Funding StatementL.V.R., S.S.R, A.A.P., and D.E.G. are funded through the National Institute on Drug Abuse (NIDA DP1DA054394, P30DA060810, P50DA037844 and R01DA059804). A.A.P., and S.S.R. are funded through the Tobacco-Related Disease Research Program (T32IR5226 and 28IR-0070). T.T.M. is supported by funds from the National Institute of Mental Health (NIMH; K08MH135343) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA; AA030083). A.D.G. is supported by NIMH Grant (R01MH120219).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Summary statistics for the SU and SUD GWAS were publicly available. Data from 23andMe are available upon request (see https://research.23andme.com/dataset-access/).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes